This review highlights key publications and abstracts in the field of radiation oncology for lung cancer in 2017 and attempts to place these in the context of developments for the broader thoracic oncology community.
Introduction
The year 2017 was a very exciting one in radiation oncology, with publications and abstracts across a range of disease presentations varying from early-stage NSCLC to oligometastatic disease, new insights into immune oncology and radiation in both the preclinical and clinical domains, and new trials in SCLC. The authors of this review have attempted to highlight some of the highimpact important developments for the broader thoracic oncology community. A number of key aspects of selected randomized trials are summarized in Table 1 .
1-10
Early-Stage NSCLC Stereotactic ablative radiation therapy (SABR) is the guideline-recommended treatment for patients presenting with medically inoperable NSCLC. [11] [12] [13] SABR replaced conventional radiotherapy in guidelines on the basis of high local control rates and low toxicity observed in single-arm studies and as population studies showed increased survival after its clinical introduction. 14 Despite this, only the randomized Scandinavian SPACE trial had until recently directly compared SABR with conventional radiotherapy. 15 Although conventional radiotherapy resulted in a poorer quality of life with significantly worse dyspnea, chest pain, and cough, the SPACE study failed to demonstrate differences in overall survival (OS) or progression-free survival (PFS). However, the failure to show other differences in outcomes in SPACE may be due to important imbalances between study arms, with more smaller tumors and female patients included in the conventional radiotherapy arm. The early findings of the TransTasman Radiation Oncology Group CHISEL trial comparing both radiation approaches were presented at the recent World Conference on Lung Cancer. 1 CHISEL enrolled patients with a confirmed diagnosis of peripherally located inoperable T1 or T2a N0 NSCLC who, after a staging positron emission tomography (PET) scan, were randomized to SABR to either 54 Gy (in three fractions) or 48 Gy (in four fractions) or to conventional radiotherapy delivered in either 6.5 weeks (66 Gy) or 4 weeks (50 Gy). SABR resulted in significantly improved local control rates, with 2-year local failure rates of 10% in the SABR arm and 40% in the conventional arm. Improved OS was seen for patients randomized to SABR, with a hazard ratio of 0.51 (p ¼ 0.020). The results of CHISEL indicate that conventional radiotherapy is not the preferred nonsurgical alternative in patients eligible to undergo SABR for a peripheral lung tumor.
In two of the large publications to date, the 5-year regional nodal recurrence rates reported after SABR for early-stage NSCLC were 12% to 13%. 16, 17 Because some patient groups may be suboptimally staged if only PET/computed tomography (CT) is performed before SABR, the prospective STAGE study (NCT02997449) evaluated the role of complete endoscopic nodal staging (endobronchial ultrasound and endoscopic ultrasound) in SABR candidates who have a centrally located or T2 peripheral located tumor or are suspected of having N1 or N2/3 nodal disease. Initial data on the study subgroup of patients without nodal metastasis after PET/CT staging (cN0) showed a nodal upstaging rate of 11% (four patients), with two patients having N1 disease and the other two having N2/N3 disease after complete hilar and mediastinal endosonographic staging performed by endobronchial ultrasound and endobronchial ultrasound by inserting the EBUS scope in the esophagus, following an endobronchial evaluation. 18 Mature data from this and two ongoing trials are awaited before the routine use of complete endoscopic nodal staging can be recommended.
A failure to distinguish expected (or "benign") features from those associated with a risk for local failure, the so-called high-risk radiologic features (HRFs), can lead to unnecessary diagnostic procedures and patient anxiety. A proposed scheme for analysis of HRFs has previously been published. 19 In 2017, the optimal surveillance imaging protocol after SABR was also addressed in a Delphi consensus process carried out by international opinion leaders in thoracic radiation oncology and radiology. 20 CT findings considered to be HRFs suggestive of a local recurrence were infiltration into adjacent structures, bulging margins, sustained growth, mass-like growth, spherical growth, craniocaudal growth, and a loss of air bronchogram. Fludeoxyglucose F 18 PET/CT scans were strongly recommended whenever there is any suspicion of a local recurrence, but its routine use otherwise was not recommended. Salvage therapy without prior pathologic confirmation of recurrence was deemed acceptable if imaging findings were considered highly suggestive, a biopsy was not safe or feasible, or an attempted biopsy was nondiagnostic. 20 This approach is important to spare futile and unnecessary salvage surgery, as highlighted by a study in which clinicians were blinded to the fact that all images were from patients without a local recurrence after SABR, but three or more HRFs were nevertheless identified in 25% of patients. 21 This suggests that biopsy confirmation is strongly preferred before salvage approaches are considered. When necessary, surgical salvage of lung recurrences after SABR may be safely performed, as was suggested by a singleinstitutional series and a literature search. 22 The accompanying literature review revealed a cumulative median OS time after salvage surgery of 47 months and a 3-year survival rate of 72%, 21 underscoring the importance of imaging and diagnostic studies after SABR.
The Delphi consensus recommended long-term follow-up after 5 years in view of the high incidence of second primary lung cancers (SPLCs). 20 This recommendation is supported by a Surveillance, Epidemiology, and End Results database analysis, which shows a rate of SPLC development of 1.1% per patient per year. 23 The standardized incidence ratios for SPLCs were highest if the initial primary lung cancer occurred at a younger age, if the patient had a previous squamous cell carcinoma, and after initial localized lung cancer. The median interval between the initial primary lung cancer and SPLC diagnoses was approximately 60 months, and the cumulative risk for development of SPLC increased over time and did not plateau, suggesting that follow-up is needed even after 5 years.
Fewer data are available on SABR outcomes for tumors larger than 5 cm or for tumors that overlap the central airways (ultracentral tumors). Patients in both of these groups have historically been excluded from clinical trials. A report on outcomes of SABR in tumors exceeding 5 cm suggested that high local control rates and acceptable survival outcomes were achieved in patients without coexisting interstitial lung disease. 24 In patients with lung cancer and coexisting interstitial lung disease who underwent SABR, a systematic review reported a weighted proportion of treatment-related deaths of 15.6%. 25 In the 2017 American Society for Radiation Oncology guidelines, SABR was considered an appropriate option for tumors exceeding 5 cm if physicians endeavored to adhere to the constraints that had been utilized in prospective studies. 13 A potential concern, however, is that full toxicity data from the key Radiation Therapy Oncology Group (RTOG) 0813 trial (National Clinical Trials identifier NCT00750269) is yet to be published, and the dose constraints used in that study were based on expert opinion. The publication of bronchial tolerance doses from a pooled study of central lung tumors has provided more data on this topic. 26 An analysis of 585 bronchial structures in 195 patients, reported clinical G3 or higher toxicity in 24 patients (12%) and radiographic bronchial toxicity in 55 patients (28%). On multivariate 
Stage III NSCLC
One highlight of 2017 was the updated survival data from the phase III RTOG 0617 trial in unresectable stage IIIA/B NSCLC, in which a 2 Â 2 factorial design was used with radiation dose and cetuximab as the two factors. 27 The primary end point was OS. A total of 496 patients were eligible for analysis, and at a median follow-up for surviving patients of 5.1 years, the median OS times were was 28.7 months versus 20.3 months for the standard-dose arm a dose of 60 Gy versus the high-dose (HD) arm receiving 74 Gy (p ¼ 0.007). Addition of cetuximab was not beneficial. The 5-year OS rates were 32% (with the standard dose) versus 23% (in the HD arm) (p ¼ 0.004), and the corresponding PFS rates were 18% and 13% (p ¼ 0.055), respectively. The survival data observed in the 60-Gy arm represent the best data to date in a phase III trial in stage IIIA/B, setting a new benchmark.
Besides the radiation dose, factors having an impact on OS in RTOG 0617 were tumor size, institution accrual, esophagitis/dysphagia, planning target volume, and heart V5. Cardiac dose in particular has garnered increased attention, with two pooled analyses of prospective trials in 2017 that correlated heart doses with cardiac events. 28, 29 However, these studies involved the use of higher, nonstandard radiotherapy schemes (medians of 74 and 70 Gy, respectively), and neither found a correlation between cardiac doses and OS. Furthermore, a secondary analysis of the phase 3 ESPATUE trial found no association between the cardiac dose parameter V5 and OS. 30 Cardiac doses might be a surrogate for unfavorable prognostic factors, especially multistation or subcarinal lymph node involvement, or for lung doses, which were not controlled for in the multivariate analysis of the RTOG 0617. 31, 32 Given the excess cardiac mortality observed in other malignancies such as Hodgkin's disease and breast cancer, appropriate use of intensity-modulated radiotherapy is justified to reduce cardiac doses in stage III NSCLC. 33 This RTOG 0617 update also provides an insight into new research priorities. There appears to be no role currently for conventionally fractionated radiation dose escalation outside the context of a clinical trial, as 17% of patients in the HD arm (p < .001) developed treatmentrelated grade 3 or higher esophagitis versus only 5% in the standard-dose arm. In addition, fewer grade 5 adverse events were seen after the standard dose. Extrathoracic recurrences represent the predominant Higher intracranial objective response rates with icotinib.
No differences in OS.
Y, yes; N, no; Ph, phase, RCT, randomized controlled trial; SABR, stereotactic ablative radiotherapy; OS, overall survival; HR, hazard ratio; CT-RT, chemoradiotherapy; PFS, progression-free survival; OD, once daily; TD, twice daily; PCI, prophylactic cranial irradiation; MRI, magnetic resonance imaging; cRT, consolidative ratiotherapy; IDMC, independent data safety monitoring committee; SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy; NS, not significant.
failure pattern (52% with the standard dose versus 58% with the HD), and local failure rates remain disappointing (38% with the standard dose versus 46% with the HD). These findings suggest that more attention to improving both distant and local control is warranted. Current treatment paradigms for stage III NSCLC have been challenged as a result of the outcomes of PACIFIC study. 3 In PACIFIC, 713 patients were randomized to either an anti-programmed death ligand 1 antibody, durvalumab, or placebo every 2 weeks for up to 12 months. Eligible patients had disease that had not progressed after at least two cycles of platinum-based chemoradiotherapy to a dose in the range of 54 to 66 Gy. A preplanned interim analysis showed that the coprimary end point of median PFS was 16.8 months in the durvalumab group versus 5.6 months in the placebo group (hazard ratio [HR] ¼ 0.52, p < 0.001). Benefit was observed in patients with the nonsquamous and squamous tumor histologic types, irrespective of programmed death ligand 1 status before the start of chemoradiotherapy and in both stages IIIA and IIIB NSCLC. From a radiation oncology viewpoint, it is important to note that objective tumor responses (i.e., infield responses) were also superior in the durvalumab arm (28.4% versus 16% [p < 0.001]). These encouraging results were achieved without significant differences in rates of clinical radiation pneumonitis, with treatment being discontinued for this reason in 6.3% of patients receiving durvalumab and 4.3% who received placebo. Currently, important details on patient characteristics and quality of radiation delivery, which include the treated tumor volumes, extent of nodal disease, use of PET staging, and radiotherapy quality aspects are unknown. However, both the randomization process and blinded independent central review of data are reassuring. Although the OS data are eagerly awaited, it must be pointed out that the PFS in stage III lung cancer has been found to correlate with OS in previous studies of chemoradiotherapy. 34 Concordant with the results of PACIFIC were a post hoc subgroup analysis of the KEYNOTE-001 study of a subgroup of 97 patients from a single institution, 42 of whom (43%) had received prior radiotherapy. 35 The median PFS after pembrolizumab was significantly longer in patients who had previously received any radiotherapy (4.4 months) as compared with in those without previous radiotherapy (2.1 months [HR ¼ 0.56, p ¼ 0.019]), as was the 6-month PFS (at 49% and 23%, respectively). This also translated into a survival advantage, with a median OS of 10.7 months versus 5.3 months, respectively (HR ¼ 0.58, p ¼ 0.026).
New data on choice of concurrent chemotherapy regimens in stage III NSCLC became available. A multicenter phase III trial in stage III NSCLC comparing the two regimens carboplatin-paclitaxel (PC) and cisplatinetoposide (PE) reported a significantly higher 3-year OS and also a higher incidence of grade 3 or higher esophagitis in the PE arm but significantly more highgrade radiation pneumonitis in the PC arm. 2 However, a systematic review of published trials comparing outcomes and toxic effects between PC and PE with concurrent thoracic radiotherapy observed no differences in median PFS, OS, or 3-year survival rates. 36 
Biomarkers in Radiotherapy
Chaudhuri et al. demonstrated the prognostic power of a deep-sequencing circulating tumor DNA (ctDNA) profiling technique called cancer personalized profiling by deep sequencing in the context of patients with NSCLC. 37 In 40 patients undergoing definitive treatment, posttreatment ctDNA was detected in plasma 20 of the 37 evaluable patients. All 20 patients experienced recurrence, with detection of ctDNA preceding radiographic progression in 17 patients by a median of 5.2 months. The first posttreatment blood sample within 4 months was defined as the landmark for minimal residual disease (MRD), which was generally the first imaging time point. The rate of freedom from progression at 36 months after the MRD landmark was 0% in patients with detectable ctDNA MRD versus 93% in those with undetectable ctDNA MRD (p < 0.001, HR ¼ 43.4). In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample. Taken together, these results indicate that ctDNA MRD in patients with lung cancer detected using cancer personalized profiling by deep sequencing may allow for personalized adjuvant treatment while the disease burden is lowest.
Oligometastatic NSCLC
There is growing acceptance that an oligometastatic disease state exists in NSCLC, and that local therapies may play a role beyond simple palliation. This is reflected in the eighth edition of the American Joint Committee on Cancer staging system, which stages a single extrathoracic metastasis (M1b) as a disease entity different from that of more widespread metastases (M1c). 38 It is in this context that a second randomized phase II trial in oligometastatic NSCLC was published; in the study, patients with up to six sites of extrathoracic disease who had stable or partial responses to first-line chemotherapy were randomized to either maintenance chemotherapy or SABR plus maintenance chemotherapy. 7 Patients receiving first-line targeted therapy for EGFR-mutated and/or ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC were excluded. An independent data safety monitoring committee closed the study early after only 29 patients had been randomized. The primary end point of PFS was significantly superior in the local consolidation therapy group (HR ¼ 0.304, p ¼ 0.01), with a median PFS of 9.7 months versus the control group PFS of 3.5 months. A multi-institutional single-arm phase II study also reported in 2017; in this study, local consolidation therapy was given to the primary and up to three sites of metastatic disease. 39 This study also closed early after 26 patients had been recruited and a median PFS of 11.2 months (95% confidence interval [CI]: 8.1-17.1) was observed.
The outcomes reported in both of the aforementioned trials were consistent with the earlier findings of Gomez et al., whose study also closed on the recommendation of an independent data safety monitoring committee. 40 The median PFS times were 11.9 months versus 3.9 months in the maintenance treatment group (HR ¼ 0.35, p ¼ 0.005). Intriguingly, the time to the appearance of a new lesion was longer among patients in the local consolidative therapy group than among patients in the maintenance treatment group (11.9 months versus 5.7 months [p ¼ 0.049]), suggesting that local control of visible disease can result in less disease progression at new sites. Taken together, the outcomes of these small prospective studies overall suggest that local consolidation can improve time to disease progression in patients with limited-volume metastatic disease when combined with systemic therapy. The question of whether this approach has an impact on OS is the subject of a number of ongoing randomized clinical trials (ClinicalTrials.gov identifiers NCT03256981, NCT02756793, NCT02417662, and NCT02759783).
Limited-Stage SCLC
The Intergroup 0096 trial was published almost 20 years ago and reported that patients with limited-stage SCLC who underwent twice-daily radiotherapy to a dose of 45 Gy in 30 fractions had higher survival rates than those who received the same dose of radiotherapy delivered in 25 once-daily fractions. 41 The median survival times were 19 months for the once-daily group and 23 months for the twice-daily group. A 10% improvement in 5-year survival was seen in the twice-daily arm (26% versus 16%), but it was unclear whether the improved outcomes were due to the higher biologically effective dose delivered with twice-daily radiotherapy, a shortening of the overall treatment time, or a combination of thereof. The recent CONVERT trial compared concurrent chemotherapy using a similar twice-daily fractionation regimen with chemotherapy and 66 Gy in 33 once-daily fractions. 4 The CONVERT study reported no differences in survival and toxicity, with median OS times being 30 months (95% CI: 24-34) and 25 months (95% CI: 21-31) for twice-daily and once-daily treatment, respectively. Less toxicity was seen than in the Intergroup 0096 trial, possibly reflecting the use of involved-field radiotherapy delivered using modern delivery techniques. Another analysis of CONVERT revealed similar toxicity and survival outcomes in patients age 70 years or older. 42 The CONVERT study was designed with the hypothesis that once-daily thoracic radiotherapy would be superior to that of twice-daily treatment, with a 12% higher OS at 2 years considered clinically significant to show superiority. Consequently, the twice-daily regimen should still be considered the standard of care, although a high-dose once-daily scheme may be an acceptable alternative.
ES-SCLC
Two studies on the use of radiotherapy in extensivestage SCLC (ES-SCLC) were published recently. An EORTC study reported 10 years ago evaluated prophylactic cranial irradiation (PCI) in patients with ES-SCLC who showed a response to induction chemotherapy, and it reported that PCI both reduced the risk of symptomatic brain metastases (BMs) (from 40% to 15%) and improved 1-year OS (from 13% to 27%). 43 Prerandomization and surveillance brain imaging was not mandatory in the EORTC study, and some argued that the effect of PCI might have been more modest had brain magnetic resonance imaging (MRI) been performed in all eligible patients. Subsequently, a Japanese study evaluated PCI versus observation in patients who underwent a brain MRI before and after chemotherapy as well as surveillance brain MRI scans at regular intervals during follow-up. The results were first presented in abstract form in 2014 and were recently published. 5 Although PCI reduced the likelihood of BMs, no significant differences in OS were seen in the PCI cohort. Most patients in the control arm (58% [64 of 111]) of the Japanese study eventually received brain radiotherapy for metastases, either as whole brain radiotherapy (WBRT) or radiosurgery. 5 The Japanese trial included older and worse-performing patients than the EORTC trial, and the trial may have been underpowered to detect realistic survival differences. 44 The conflicting OS outcomes in the Japanese and EORTC trials have led guidelines to acknowledge PCI and MRI surveillance with early salvage radiation as acceptable strategies for ES-SCLC 45 ; further trials are likely necessary to resolve this equipoise in the modern era.
An RTOG study in patients with ES-SCLC compared the combination of PCI, thoracic radiotherapy, and radiotherapy of metastatic sites with PCI only. 6 The study closed prematurely on account of futility, and after a median follow-up of 9 months, the researchers reported a significant difference in PFS in favor of consolidative radiotherapy to the thorax and metastatic sites but with no significant difference in OS, which was the primary study end point. 6 After consolidative radiotherapy, the risk of locoregional disease as a component of first site of failure decreased from 63% to 26% and progression rates at initial sites of disease decreased from 78% to 42%. Future trials should aim at identifying which patients are most likely to benefit from more aggressive local radiotherapy for oligometastatic SCLC.
When the results of the two recent randomized controlled trials (RCTs) in ES-SCLC presented in 2017 5, 6 are compared with the results of the earlier EORTC 43 and CREST 46 studies, large differences are seen in median OS (Table 2 5,6,43,46 ). As both of the studies reporting in 2017 accrued much more slowly and included patients who had a longer OS, this raises the possibility of some element of selection bias in these studies.
BMs
Lung cancer remains the leading cause of BMs, and several key studies were reported in 2017. In surgically resected BMs, an RCT of postoperative stereotactic radiosurgery (SRS) to the surgical cavity versus observation demonstrated improved local control with SRS (12-month rate 72% versus 43%), with no differences in OS. 8 Another RCT of postoperative SRS versus WBRT demonstrated improved cognitive preservation with SRS and no difference in OS. 9 These trials establish the role of postoperative SRS for resected BMs; however, the suboptimal local controls with postoperative SRS in these studies (72% and 61%) underscore efforts to optimize SRS dose, fractionation, and technique in the postoperative setting. 47 Secondary analyses of the data set from the EORTC 22952 showed no OS benefit with addition of WBRT irrespective of extracranial disease status or NSCLC prognostic group 48 and provide a counterpoint to a prior JROSG-991 analysis suggesting improved OS with WBRT in these patients. 49 An update of the JLGK-0901 prospective study of SRS alone for one to 10 BMs demonstrated good cognitive preservation and low rates of SRS toxicity. 50 These data provide continued support for SRS alone for multiple BMs in carefully selected patients undergoing close central nervous system (CNS) surveillance; randomized trials of SRS versus WBRT for four or more metastases are ongoing (NCT01592968 and NCT02353000).
Strategies of upfront treatment using tyrosine kinase inhibitors (TKIs) alone in oncogene-addicted NSCLC with BM have been proposed to reduce toxicity from WBRT. An RCT comparing icotinib with WBRT plus chemotherapy in EGFR-mutated NSCLC with three or more BMs found improved CNS PFS with icotinib (10.0 versus 4.8 months) 10 ; however, more clinically relevant questions regarding optimal combinations and sequencing of TKIs and CNS radiation remain. A multicenter retrospective study of EGFR-mutated NSCLC with BM cautioned omission of upfront CNS radiation, reporting improved OS with SRS (46 months) or WBRT (30 months) plus a TKI versus with a TKI alone (25 months). 51 Today, early CNS radiation remains the standard for NSCLC BM regardless of molecular status. However, as systemic agents demonstrate increasing CNS activity and blur the lines of distinction between response rates in the body and the brain, 52 ,53 the next generation of trials will need to address optimal multidisciplinary management of BM with local and systemic therapies.
Conclusion
The developments highlighted in this review clearly reveal the progress made in this area in 2017, with much potential for establishing new standards of care, including a better integration of radiation with systemic therapies in the treatment of lung cancer. 
